CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On August9, 2017, Cempra, Inc. issued a press release announcing its operating results for the second quarter ended June30, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02. Financial Statements and Exhibits.
| (d) Exhibits | |
|
ExhibitNo. |
Description |
| 99.1 | Press release dated August 9, 2017 to report second quarter 2017 results of operations. |
CEMPRA, INC. ExhibitEX-99.1 2 d440718dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CEMPRA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS —Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL,…To view the full exhibit click here
About CEMPRA, INC. (NASDAQ:CEMP)
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
